SURMOUNT trial programme: difference between revisions
Diff·revision 20 → 21·12:58, 2 Aug 2025
Difference between revision 20 and revision 21 of SURMOUNT trial programme. 3 lines changed; the page grew by 149 bytes.
| Revision 20 — 11:46, 10 Jul 2025 Chromatokid (talk) add the trial registration identifier 4,572 bytes ±0 | Revision 21 — 12:58, 2 Aug 2025 B12_Bettina (talk) the percentage quoted was placebo-adjusted; label it 4,721 bytes +149 | ||
|---|---|---|---|
| 46 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 46 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| 47 | 47 | ||
| + | 48 | == External links == | |
| + | 49 | * [https://clinicaltrials.gov/study/NCT04184622 SURMOUNT-1 — NCT04184622] — Registry record for the pivotal obesity trial. | |
| + | 50 | ||
| 48 | == See also == | 51 | == See also == |
| 49 | * [[Tirzepatide]] | 52 | * [[Tirzepatide]] |